Lenalidomide and nivolumab added to standard treatment for brain lymphoma
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This Phase 1 trial tests adding two cancer medicines—lenalidomide and nivolumab—to the usual treatment for primary CNS diffuse large B-cell lymphoma (a type of lymphoma in the brain/spinal fluid). The goal is to see if the combination is safe and if it works better than the usual approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult (18 or older) with primary CNS diffuse large B-cell lymphoma confirmed by brain tissue, spinal fluid, or eye fluid testing.
- You must not have had prior chemotherapy or radiation for lymphoma, and you must not have had an allogeneic stem cell transplant (donor transplant).
- You must not have had an organ transplant before (this trial needs to rule out certain transplant-related lymphoma).
- Your body must be able to handle treatment: blood counts (ANC and platelets), kidney function, and liver tests must be within allowed ranges.
- You must not have certain conditions that can increase risks—such as active autoimmune disease needing immune-suppressing medications, uncontrolled infections (HIV, active HBV, or active HCV), or other ongoing cancers requiring treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether lenalidomide and rituximab can help keep primary CNS lymphoma from coming back after initial chemotherapy. It may be an option if you cannot do a transplant and you can take pills.
This trial tests a combination of radiation, immune-boosting drugs, and a targeted antibody for people newly diagnosed with primary central nervous system diffuse large B-cell lymphoma (a type of brain lymphoma). The goal is to see if this approach is safe and effective.
This Phase 2 study tests a combination treatment to shrink primary central nervous system lymphoma that starts in the brain, spinal cord, meninges, or eye. It may help patients who have not had anti-cancer treatment yet, but it requires specific cancer type and health conditions.
This Phase 2 trial studies methotrexate, tafasitamab, lenalidomide, and rituximab for primary B-cell lymphoma that starts in the brain/spinal fluid. It aims to see how well this combination works for people who cannot have certain high-dose stem cell treatment.
This trial tests a combination of three drugs (pomalidomide, rituximab, and methotrexate) for people who have just been diagnosed with a type of lymphoma that started in the brain or spinal cord. The goal is to see if this drug cocktail is safe and effective as a first treatment.
This trial tests a combination of the immunotherapy drug pembrolizumab (Keytruda) with standard chemotherapy for people newly diagnosed with primary CNS lymphoma. The goal is to see if adding pembrolizumab can improve outcomes compared to chemotherapy alone.
Hear when a new Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.